Skip to main content
Yabao Pharmaceutical Group Co.,Ltd logo

Yabao Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600351 ISIN · CNE000001CM5 LEI · 65560071PKRS4UHMVU53 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,362 across all filing types
Latest filing 2023-05-08 AGM Information
Country CN China
Listing Shanghai Stock Exchange 600351

About Yabao Pharmaceutical Group Co.,Ltd

http://www.yabao.com.cn

Yabao Pharmaceutical Group Co.,Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceutical products. The company maintains a specialized portfolio across therapeutic areas including pediatrics, cardiovascular health, and endocrinology. Key offerings include traditional Chinese medicines, chemical drugs, and innovative transdermal patches, such as the Dinggui Erqi Patch. The organization operates integrated production bases and research facilities dedicated to advancing drug delivery systems and biotechnological applications. Its business model emphasizes the modernization of traditional therapies alongside the development of conventional pharmaceuticals to address diverse clinical needs.

Recent filings

Filing Released Lang Actions
亚宝药业集团股份有限公司2022年年度股东大会会议资料
AGM Information Classification · 100% confidence The document is titled "亚宝药业集团股份有限公司 2022 年年度股东大会会议资料" which translates to "Yabao Pharmaceutical Group Co., Ltd. 2022 Annual General Meeting Materials." It contains detailed information about the 2022 Annual General Meeting (AGM), including meeting notices, agenda, voting procedures, reports to be reviewed and approved at the AGM such as the 2022 annual report, board reports, supervisory board reports, independent directors' reports, financial statements, profit distribution plans, and appointment of auditors. The document also includes detailed descriptions of the company's operations, financial performance, governance, and management reports as part of the AGM materials. The length is substantial (15,000 characters), and the content is clearly the presentation and materials shared during the AGM rather than just an announcement or a proxy statement. Therefore, the document fits the category of AGM Information (AGM-R).
2023-05-08 Chinese
亚宝药业集团股份有限公司关于以集中竞价交易方式回购股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of a share repurchase program by the company 亚宝药业集团股份有限公司. It details the approval of the share buyback plan, the funding limits, price limits, and the status of the repurchase as of a certain date. There are no financial statements or detailed financial data included, only an update on the share repurchase activity. This fits the definition of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back or selling its own shares.
2023-05-04 Chinese
亚宝药业集团股份有限公司关于参加山西辖区上市公司2023年投资者网上集体接待日活动的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by the company about its participation in an investor online collective reception day event organized by regulatory and industry bodies. It mentions the date and time of the event and topics to be discussed, including 2022 annual performance, governance, strategy, financing plans, and sustainability. The document does not contain any financial statements, detailed financial data, or report content itself. It is an announcement of an investor event rather than a report or transcript. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-05-04 Chinese
亚宝药业独立董事提名人声明（二）
Board/Management Information Classification · 95% confidence The document is a formal statement nominating an independent director candidate for the company's board. It details the qualifications, independence criteria, and compliance with relevant laws and regulations for the nominee. There is no financial data, no report or results announcement, and no mention of voting results or meeting materials. This is a management or board-related announcement concerning director nomination, which fits the category of Board/Management Information (MANG). The document length is short and focused solely on the nomination statement, confirming it is not a full report or regulatory filing.
2023-04-25 Chinese
亚宝药业集团股份有限公司2022年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2022 年年度报告摘要" which translates to "2022 Annual Report Summary". It contains detailed financial data for the year 2022, including total assets, net profit, earnings per share, quarterly financial data, shareholder information, and business overview. The document references an audit report with an unqualified opinion, which is typical for annual reports. The length of the document (9100 characters) and the detailed financial and operational data indicate this is the actual annual report summary, not just an announcement or a brief. The content aligns with the definition of an Annual Report (10-K) as it covers company activity and full financial performance for the fiscal year. Therefore, the correct classification is Annual Report (10-K). FY 2022
2023-04-25 Chinese
亚宝药业集团股份有限公司2022年度利润分配预案公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as a "2022年度利润分配预案公告" which translates to "2022 Annual Profit Distribution Plan Announcement." It details the proposed cash dividend per share, total dividend amount, and the basis for distribution. It mentions that the plan was approved by the board and will be submitted to the annual shareholders meeting for approval. The document does not contain full financial statements or comprehensive financial performance data but focuses on the dividend distribution plan. The length is short (1263 characters), and it is an announcement of a dividend distribution plan rather than the actual dividend payment or a full annual report. Therefore, it fits best under the category of Notice of Dividend Amount (DIV).
2023-04-25 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.